BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou T, Liao C, Li HY, Lin W, Lin S, Zhong H. Efficacy of mesenchymal stem cells in animal models of lupus nephritis: a meta-analysis. Stem Cell Res Ther 2020;11:48. [PMID: 32019582 DOI: 10.1186/s13287-019-1538-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Shi Y, Jiang N, Li M, Zeng X, Tian X. Mesenchymal stem cells and connective tissue diseases: From bench to bedside. Journal of Translational Internal Medicine 2022;0. [DOI: 10.2478/jtim-2022-0028] [Reference Citation Analysis]
2 Wang HS, Yi MY, Wu X, Liu Q, Deng YH, Wu T, Wang L, Kang YX, Luo XQ, Yan P, Wang M, Duan SB. Effects of mesenchymal stem cells in renovascular disease of preclinical and clinical studies: a systematic review and meta-analysis. Sci Rep 2022;12:18080. [PMID: 36302933 DOI: 10.1038/s41598-022-23059-2] [Reference Citation Analysis]
3 Quaglia M, Merlotti G, Fornara L, Colombatto A, Cantaluppi V. Extracellular Vesicles Released from Stem Cells as a New Therapeutic Strategy for Primary and Secondary Glomerulonephritis. Int J Mol Sci 2022;23:5760. [PMID: 35628570 DOI: 10.3390/ijms23105760] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Jasim SA, Yumashev AV, Abdelbasset WK, Margiana R, Markov A, Suksatan W, Pineda B, Thangavelu L, Ahmadi SH. Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases. Stem Cell Res Ther 2022;13:101. [PMID: 35255979 DOI: 10.1186/s13287-022-02782-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
5 Huang F, Thokerunga E, He F, Zhu X, Wang Z, Tu J. Research progress of the application of mesenchymal stem cells in chronic inflammatory systemic diseases. Stem Cell Res Ther 2022;13:1. [PMID: 34998430 DOI: 10.1186/s13287-021-02613-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
6 Yi H, Wang Y, Liang Q, Mao X. Preclinical and Clinical Amelioration of Bone Fractures with Mesenchymal Stromal Cells: a Systematic Review and Meta-Analysis. Cell Transplant 2022;31:9636897211051743. [PMID: 35916286 DOI: 10.1177/09636897211051743] [Reference Citation Analysis]
7 Li A, Guo F, Pan Q, Chen S, Chen J, Liu HF, Pan Q. Mesenchymal Stem Cell Therapy: Hope for Patients With Systemic Lupus Erythematosus. Front Immunol 2021;12:728190. [PMID: 34659214 DOI: 10.3389/fimmu.2021.728190] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
8 Calcat-I-Cervera S, Sanz-Nogués C, O'Brien T. When Origin Matters: Properties of Mesenchymal Stromal Cells From Different Sources for Clinical Translation in Kidney Disease. Front Med (Lausanne) 2021;8:728496. [PMID: 34616756 DOI: 10.3389/fmed.2021.728496] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
9 Jiang B, Yao G, Tang X, Yang X, Feng X. MSCs relieve SLE by modulation of Th17 cells through MMPs–CCL2–CCR2–IL‐17 pathway. Rheumatology & Autoimmunity 2021;1:30-9. [DOI: 10.1002/rai2.12002] [Reference Citation Analysis]
10 El-Jawhari JJ, El-Sherbiny Y, McGonagle D, Jones E. Multipotent Mesenchymal Stromal Cells in Rheumatoid Arthritis and Systemic Lupus Erythematosus; From a Leading Role in Pathogenesis to Potential Therapeutic Saviors? Front Immunol 2021;12:643170. [PMID: 33732263 DOI: 10.3389/fimmu.2021.643170] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
11 Lin S, Lin W, Liao C, Zhou T. Nephroprotective Effect of Mesenchymal Stem Cell-Based Therapy of Kidney Disease Induced by Toxicants. Stem Cells Int 2020;2020:8819757. [PMID: 33424979 DOI: 10.1155/2020/8819757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Askenase PW. COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies? J Extracell Vesicles 2020;10:e12004. [PMID: 33304473 DOI: 10.1002/jev2.12004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
13 Lee HK, Kim HS, Pyo M, Park EJ, Jang S, Jun HW, Lee TY, Kim KS, Bae SC, Kim Y, Hong JT, Yun J, Han SB. Phorbol ester activates human mesenchymal stem cells to inhibit B cells and ameliorate lupus symptoms in MRL.Fas lpr mice. Theranostics 2020;10:10186-99. [PMID: 32929342 DOI: 10.7150/thno.46835] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
14 Soto M, Delatorre N, Hurst C, Rodgers KE. Targeting the Protective Arm of the Renin-Angiotensin System to Reduce Systemic Lupus Erythematosus Related Pathologies in MRL-lpr Mice. Front Immunol 2020;11:1572. [PMID: 32793221 DOI: 10.3389/fimmu.2020.01572] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]